Brentuximab vedotin is a drug used to treat Hodgkin lymphoma that has returned or continued to grow despite therapy. It has two parts: one (an antibody) that attaches to a protein on the surface of cancer cells called CD30, and another (an anticancer drug called monomethyl auristatin E) that kills the cancer. Temsirolimus is approved for the treatment of advanced kidney cancer, but its use in Hodgkin lymphoma is considered investigational. It works on a protein called mTOR.
While brentuximab vedotin and temsirolimus have different ways of working, laboratory studies suggest that they have more anticancer activity when combined. The purpose of this study is to assess the safety and effectiveness of giving both of these drugs in patients with Hodgkin lymphoma that has returned or continued to grow despite a stem cell transplant or two prior regimens of therapy. Both drugs are given intravenously (by vein).